IN2014MN02126A - - Google Patents

Info

Publication number
IN2014MN02126A
IN2014MN02126A IN2126MUN2014A IN2014MN02126A IN 2014MN02126 A IN2014MN02126 A IN 2014MN02126A IN 2126MUN2014 A IN2126MUN2014 A IN 2126MUN2014A IN 2014MN02126 A IN2014MN02126 A IN 2014MN02126A
Authority
IN
India
Prior art keywords
compounds
calcium
crac
channel
formula
Prior art date
Application number
Other languages
English (en)
Inventor
Nageswara Rao Irlapati
Zubair Abdul Wajid Shaikh
Vijay Pandurang Karche
Gokul Keruji Deshmukh
Neelima Sinha
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Priority to IN2126MUN2014 priority Critical patent/IN2014MN02126A/en
Publication of IN2014MN02126A publication Critical patent/IN2014MN02126A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN2126MUN2014 2012-05-02 2013-05-01 IN2014MN02126A (enExample)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN2126MUN2014 IN2014MN02126A (enExample) 2012-05-02 2013-05-01

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN6KO2012 2012-05-02
PCT/IB2013/053440 WO2013164769A1 (en) 2012-05-02 2013-05-01 Substituted pyridine compounds as crac modulators
IN2126MUN2014 IN2014MN02126A (enExample) 2012-05-02 2013-05-01

Publications (1)

Publication Number Publication Date
IN2014MN02126A true IN2014MN02126A (enExample) 2015-09-11

Family

ID=48428565

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2126MUN2014 IN2014MN02126A (enExample) 2012-05-02 2013-05-01

Country Status (7)

Country Link
US (2) US9399638B2 (enExample)
EP (1) EP2844655A1 (enExample)
AU (1) AU2013255437A1 (enExample)
CA (1) CA2871270A1 (enExample)
IN (1) IN2014MN02126A (enExample)
WO (1) WO2013164769A1 (enExample)
ZA (1) ZA201407685B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10703722B2 (en) 2010-04-27 2020-07-07 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9725463B2 (en) 2013-06-21 2017-08-08 Lupin Limited Substituted heterocyclic compounds as CRAC modulators
CA2914415A1 (en) 2013-06-24 2014-12-31 Lupin Limited Chromane and chromene derivatives and their use as crac modulators
WO2015090579A1 (en) * 2013-12-18 2015-06-25 Grünenthal GmbH Pyrazolyl-based carboxamides iv
CN105367547B (zh) * 2014-08-19 2019-04-23 北京桦冠生物技术有限公司 一种噁唑啉酮抗生素的新合成工艺
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CA2968299A1 (en) 2014-11-18 2016-05-26 Rutgers, The State University Of New Jersey Novel mitochondrial uncouplers for treatment of metabolic diseases and cancer
ES3033759T3 (en) * 2015-02-27 2025-08-07 Calcimedica Inc Pancreatitis treatment
CN107847548B (zh) 2015-05-18 2022-06-14 贝思以色列女会吏医学中心公司 P物质、肥大细胞脱颗粒抑制剂和周围神经病
SMT201900427T1 (it) * 2015-06-03 2019-09-09 Bristol Myers Squibb Co Agonisti di apj a base di 4-idrossi-3-(eteroaril)piridin-2-one per l'uso nel trattamento di disturbi cardiovascolari
WO2017027400A1 (en) 2015-08-07 2017-02-16 Calcimedica, Inc. Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury
CN109415363B (zh) 2016-05-18 2021-07-20 罗格斯,新泽西州立大学 用于治疗代谢疾病和癌症的新的线粒体解偶联剂
EP3515446B1 (en) 2016-09-19 2023-12-20 Novartis AG Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
CA3057969A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
IL275522B2 (en) * 2017-12-22 2024-02-01 Petra Pharma Corp Amine derivatives of ARYL–BIPYRIDINE as phosphatidylinositol phosphate kinase inhibitors
PE20251292A1 (es) 2018-03-08 2025-05-14 Incyte Corp Compuestos diolicos de aminopirazina como inhibidores de pi3k-gamma
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
BR112021004893A2 (pt) 2018-09-14 2021-06-01 Rhizen Pharmaceuticals A G composições compreendendo um inibidor de crac e um corticosteroide e métodos de uso dos mesmos
AU2020276695B2 (en) 2019-05-13 2025-12-18 Novartis Ag New crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as RAF inhibitors for the treatment of cancer
CN110407740A (zh) * 2019-09-04 2019-11-05 上海毕得医药科技有限公司 一种3-溴-2-乙基吡啶的合成方法
EP4243813A4 (en) 2020-11-13 2024-07-17 Calcimedica, Inc. IMPROVED SYNTHESIS OF CRAC CHANNEL INHIBITORS
AU2023261084A1 (en) 2022-04-25 2024-11-14 Nippon Shinyaku Co., Ltd. Compound serving as ddr1 kinase inhibitor, and medicine

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI332832B (en) 2003-07-23 2010-11-11 Synta Pharmaceuticals Corp Method for modulating calcium ion-release-activated calcium ion channels
MX2007003342A (es) 2004-09-21 2007-06-05 Synta Pharmaceutical Corp Compuestos para inflamacion y usos relacionados con trastornos inmunitarios.
WO2006083477A2 (en) 2005-01-07 2006-08-10 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
AU2006208045B2 (en) 2005-01-25 2012-08-30 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
WO2006081389A1 (en) 2005-01-25 2006-08-03 Synta Pharmaceuticals Corp. Thiophene compounds for inflammation and immune-related uses
US20070275960A1 (en) 2006-01-25 2007-11-29 Synta Pharmaceuticals Corp. Phenyl and pyridyl compounds for inflammation and immune-related uses
WO2007087441A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted aromatic compounds for inflammation and immune-related uses
TW200806290A (en) 2006-01-25 2008-02-01 Synta Pharmaceuticals Corp Substituted biaryl compounds for inflammation and immune-related uses
TW200800188A (en) 2006-01-31 2008-01-01 Synta Pharmaceuticals Corp Pyridylphenyl compounds for inflammation and immune-related uses
AU2007286807B2 (en) 2006-08-21 2013-03-21 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
TW200911800A (en) 2007-08-01 2009-03-16 Synta Pharmaceuticals Corp Pyridine compounds for inflammation and immune-related uses
KR101541558B1 (ko) 2007-08-17 2015-08-03 액테리온 파마슈티칼 리미티드 S1p1/edg1 수용체 조절제로서의 피리딘 유도체
AU2008299220B2 (en) 2007-09-10 2011-07-21 Calcimedica, Inc. Compounds that modulate intracellular calcium
US8389567B2 (en) 2007-12-12 2013-03-05 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP5474941B2 (ja) 2008-05-23 2014-04-16 グラクソ グループ リミテッド 窒素含有三環式化合物およびその抗菌剤としての使用
DE102008031299B4 (de) 2008-07-02 2014-10-30 Acandis Gmbh & Co. Kg Filter für ein Blutgefäß
CN102256969A (zh) 2008-08-27 2011-11-23 钙医学公司 调节胞内钙的化合物
US8524763B2 (en) 2008-09-22 2013-09-03 Calcimedica, Inc. Inhibitors of store operated calcium release
US20100130522A1 (en) 2008-10-01 2010-05-27 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
WO2011024004A1 (en) 2009-08-26 2011-03-03 Astrazeneca Ab Heterocyclic urea derivatives useful for treatment of bacterial infection
EP2477982A4 (en) 2009-09-16 2013-04-03 Calcimedica Inc COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM
PL2632906T3 (pl) 2010-10-30 2016-09-30 Oksazolinowe i izoksazolinowe pochodne jako modulatory kanałów typu CRAC
ES2660996T3 (es) 2011-05-03 2018-03-27 PRCL Research Inc. Compuestos para la inflamación y usos relacionados con el sistema inmunitario
WO2013059677A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013059666A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium

Also Published As

Publication number Publication date
US9399638B2 (en) 2016-07-26
WO2013164769A1 (en) 2013-11-07
US20150111900A1 (en) 2015-04-23
CA2871270A1 (en) 2013-11-07
AU2013255437A1 (en) 2014-11-13
EP2844655A1 (en) 2015-03-11
ZA201407685B (en) 2015-11-25
US20160304506A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
IN2014MN02126A (enExample)
IN2014MN02127A (enExample)
CO6430427A2 (es) Derivados de benzofuranilo
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MX2013012896A (es) Compuestos novedosos como moduladores de proteina cinasas.
GEP20166438B (en) Imidazopyrrolidinone compounds
PH12015500551A1 (en) Tricyclic quinoline and quinoline derivatives
CR20110103A (es) Heteroarilos sustituidos
IN2014CN04907A (enExample)
MD20140109A2 (ro) Compuşi ai indolului şi indazolului care activează AMPK
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
MX2015012478A (es) Metodos y composiciones para inhibicion de proteinas que contienen bromodominio.
WO2012170931A3 (en) Compounds that modulate intracellular calcium
IN2012DN00943A (enExample)
MX2015012867A (es) Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
MX337711B (es) Compuestos que modulan el calcio intracelular.
PH12014501979A1 (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
TN2013000346A1 (en) Asymmetric ureas and medical uses thereof
PH12013500831A1 (en) Oxazoline and isoxazoline derivatives as crac modulators
PH12014501891B1 (en) Substituted chroman compounds as calcium sensing receptor modulators
WO2012170951A3 (en) Compounds that modulate intracellular calcium
AU2011322715A8 (en) Treatment of MeCP2-associated disorders
UY36081A (es) Compuestos inhibidores de metaloenzima como fungicidas.
TW201613878A (en) Pyrazine GPR40 agonists for the treatment of type II diabetes